EVs driving India's Next Growth Story: MoS (See 'Corp Brief') Meditation is scientific tool for stress management and neuroplasticity: Experts (See 'Corp Brief') Misc - Directors of company under winding up are statutorily bound under Section 454 of Companies Act, to make full and accurate disclosure of assets: HC (See 'Legal Desk') Mandaviya leads 1st Anniversary Celebrations of Fit India Sundays on Cycle in Puducherry (See 'Corp Brief') MoHUA launches 10th Swachh Survekshan (See 'Corp Brief') Misc - Once CIRP is initiated, all claims against corporate debtor must be routed through insolvency process: HC (See 'Legal Desk') Centre releases grants of Rs 94 Crores for PRIs in Uttarakhand (See 'Corp Brief') New Logo for RRBs signifying single and unified brand identity unveiled (See 'Corp Brief') PMVBRY aims to incentivise creation of over 3.5 crore jobs over 2 years (See 'Corp Brief') IPR - Pharmaceutical guidelines illustrate that if combination of two prior art documents fails to provide result as claimed in invention in question, then teaching of prior art documents is considered to be teaching away: HC (See 'Legal Desk') Ministry of Parliamentary Affairs transforming functioning into paperless ecosystem (See 'Corp Brief') Scindia chairs review meeting on Matabari Tourism Circuit Development in Tripura (See 'Corp Brief') IPR - If Novartis had consciously waived its right to cross-examination by electing to file rebuttal evidence, there are no valid grounds to challenge Controller's order: HC (See 'Legal Desk') WHO Global Summit on Traditional Medicine Commences in New Delhi (See 'Corp Brief') MoS delivers national statement at UN on outcomes of World Summit on the Information Society (See 'Corp Brief') PM MITRA Parks anchored in 5F vision generating huge investment interest (See 'Corp Brief') IPR - While assessing 'prior art', mere similarity is insufficient and visual distinction matters, and for prior art to invalidate design, it must be clearly established and comparable in relevant features: HC (See 'Legal Desk') Steps taken to strengthen security of cyber ecosystem (See 'Corp Brief') ICG Ship Sarthak makes Strategic Port Call at Chabahar (See 'Corp Brief') IPR - On being satisfied that brand or mark has acquired status which is well known, there ought to be order directing that no individuals should be allowed to register UPI Ids or VPAs with said brand names: HC (See 'Legal Desk') CCI okays acquisition of paper & pulp manufacturing business of ABREL by ITC Ltd (See 'Corp Brief') CCI okays acquisition of equity stake in Logisteed Holdings, Ltd. by Japan Post Co., Ltd. (See 'Corp Brief') CCI nod to proposed combination involving acquisition of minority shareholding in DCX Global Limited by Coinbase Global Inc. (See 'Corp Brief') IBC - Compromise between bank and co-guarantor did not extinguish liability of other guarantors, who issued separate, enforceable undertakings: HC (See 'Legal Desk')

Print

NPPA monitors prices of scheduled & non-scheduled medicines

Published: Jul 30, 2024

By TIOLCorplaws News Service

NEW DELHI, JULY 30, 2024: AS per the provisions of Drugs (Prices Control) Order, 2013 (DPCO, 2013), formulations listed in Schedule-I of the DPCO are defined as scheduled formulation under section 2(1)(zb) of DPCO, 2013. Formulations not included in Schedule-I are defined under Para 2(1)(v) of DPCO, 2013 as non-scheduled formulation. Thus, both schedule and non-schedule drugs are covered under DPCO, 2013. 

As per the extant provisions of DPCO, 2013, the ceiling prices of scheduled medicines are revised annually on the basis of Wholesale Price Index (WPI) (all commodities) for preceding calendar year by National Pharmaceutical Pricing Authority (NPPA), on or before 1st April of every year and is notified by the Government on the 1st day of April every year. The details of price fixed by NPPA are available at NPPA's website i.e. nppaindia.nic.in.  In case of non-scheduled formulation (branded or generic), as per para 20 of DPCO, 2013, no manufacturers can increase Maximum Retail Price (MRP) by more than 10% of MRP during preceding 12 months.  The maximum permissible increase in prices, as per the provisions of DPCO, 2013 for scheduled and non-scheduled drugs may or may not be availed by their respective manufacturers based on commercial considerations and market dynamics.

Under the Drugs and Cosmetics Act, 1945 and Rules thereunder, manufacturers of drugs are required to comply with conditions of manufacturing licence and the requirements of Good Manufacturing Practices (GMP).  As per the Drugs Rules, 1945, the manufacturing, testing, labeling, packaging, storage and distribution are required to be carried out in compliance with the conditions of license including the Good manufacturing practices (GMP) prescribed under the Schedule M of the Drugs Rules, 1945. In case of violation, the Licensing Authority is empowered to take action as per the said Act and Rules.

NPPA monitors the prices of scheduled as well as non-scheduled medicines under DPCO, 2013.  Action is taken against companies, found selling formulations at prices higher than the permissible price, and the overcharged amount is recovered from the company as per the relevant provisions of the DPCO, 2013. During the financial year 2023-24, Rs. 72.73 crore was recovered from the defaulting companies.

This information was given by the Union Minister of State for Chemicals and Fertilizers Anupriya Patel in Rajya Sabha in reply to a question today.

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
tioltube
TKF
TIOLawards
A TIOL Website. Copyright © 2025 TIOLcorplaws.com All rights reserved.